Clinical trial
Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral…
NCT00039195 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00039195 |
|---|---|
| Title | Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma |
| Official title | Risk-Adapted Therapy for Patients With Untreated Age-Adjusted International Prognostic Index II or III Diffuse Large B Cell Lymphoma |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH Bristol-Myers Squibb Industry Genentech, Inc. |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug, Procedure, Radiation |
| Interventions | filgrastim, rituximab, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, prednisone, vincristine sulfate, peripheral blood stem cell transplantation and 1 more |
| Enrollment | 98 |
| Start date | Nov 1, 2006 |
| Primary completion | Jan 1, 2010 |
| Completion | Jan 1, 2010 |
| First posted | Jan 27, 2003 |
| Last update posted | Aug 10, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: